New Zealand markets open in 4 hours 19 minutes

Amylyx Pharmaceuticals, Inc. (AMLX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8350+0.0800 (+4.56%)
As of 01:41PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 119.35M
Enterprise value -250.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.31
Price/book (mrq)0.37
Enterprise value/revenue 6.45k
Enterprise value/EBITDA -11.71

Trading information

Stock price history

Beta (5Y monthly) -0.68
52-week change 3-93.76%
S&P500 52-week change 326.27%
52-week high 329.2350
52-week low 31.7000
50-day moving average 34.0919
200-day moving average 313.9161

Share statistics

Avg vol (3-month) 33.57M
Avg vol (10-day) 31.8M
Shares outstanding 568.01M
Implied shares outstanding 672.85M
Float 851.52M
% held by insiders 114.23%
% held by institutions 1102.48%
Shares short (30 Apr 2024) 48.51M
Short ratio (30 Apr 2024) 43.53
Short % of float (30 Apr 2024) 413.78%
Short % of shares outstanding (30 Apr 2024) 412.52%
Shares short (prior month 28 Mar 2024) 46.01M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -17.86%
Operating margin (ttm)-137.78%

Management effectiveness

Return on assets (ttm)-12.31%
Return on equity (ttm)-21.00%

Income statement

Revenue (ttm)398M
Revenue per share (ttm)5.89
Quarterly revenue growth (yoy)24.10%
Gross profit (ttm)N/A
EBITDA -80.08M
Net income avi to common (ttm)-71.09M
Diluted EPS (ttm)-1.0700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)373.29M
Total cash per share (mrq)5.49
Total debt (mrq)3.69M
Total debt/equity (mrq)1.14%
Current ratio (mrq)4.48
Book value per share (mrq)4.77

Cash flow statement

Operating cash flow (ttm)16.5M
Levered free cash flow (ttm)34.87M